Cargando…

Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity

AIMS: The CHHiP (Conventional or Hypofractionated High-dose Intensity Modulated Radiotherapy In Prostate Cancer; CRUK/06/016) trial investigated hypofractionated radiotherapy for localised prostate cancer. Forward- (FP) or inverse-planned (IP) intensity-modulated techniques were permitted. Dose–volu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naismith, O.F., Griffin, C., Syndikus, I., South, C., Mayles, H., Mayles, P., Khoo, V., Scrase, C., Graham, J., Hassan, S., Hall, E., Dearnaley, D.P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	W.B. Saunders 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688097/ https://www.ncbi.nlm.nih.gov/pubmed/31178346 http://dx.doi.org/10.1016/j.clon.2019.05.002

Ejemplares similares

Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial
por: Murray, Julia, et al.
Publicado: (2019)

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
por: Dearnaley, David, et al.
Publicado: (2016)

Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial
por: Brand, Douglas H., et al.
Publicado: (2021)

Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)
por: Staffurth, John N., et al.
Publicado: (2021)

Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial
por: Tree, Alison, et al.
Publicado: (2022)

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
por: Wilkins, Anna, et al.
Publicado: (2015)

Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation
por: Wilkins, Anna, et al.
Publicado: (2023)

A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer
por: Murray, Julia, et al.
Publicado: (2020)

Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicity
por: Lemanska, Agnieszka, et al.
Publicado: (2017)

Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)
por: Dearnaley, David, et al.
Publicado: (2019)

Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practice
por: Lemanska, Agnieszka, et al.
Publicado: (2020)

Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer
por: Wilkins, Anna, et al.
Publicado: (2018)

PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018)
por: Syndikus, Isabel, et al.
Publicado: (2020)

Accuracy and Reproducibility of Conformal Radiotherapy using Data from a Randomised Controlled Trial of Conformal Radiotherapy in Prostate Cancer (MRC RT01, ISRCTN47772397)
por: Stanley, S., et al.
Publicado: (2008)

Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer
por: Ferreira, M.R., et al.
Publicado: (2019)

Should perioperative immune-modulating nutrition therapy be the standard of care? A systematic review
por: Weitzel, LB, et al.
Publicado: (2009)

Late Gastrointestinal Toxicity After Dose-Escalated Conformal Radiotherapy for Early Prostate Cancer: Results From the UK Medical Research Council RT01 Trial (ISRCTN47772397)
por: Syndikus, Isabel, et al.
Publicado: (2010)

A multicentre study of the evidence for customized margins in photon breast boost radiotherapy
por: Harris, Emma J, et al.
Publicado: (2016)

Gastrointestinal Toxicity Prediction Not Influenced by Rectal Contour or Dose-Volume Histogram Definition
por: Brand, Douglas H., et al.
Publicado: (2023)

Comparison of Rapid Arc and Intensity-modulated Radiotherapy Plans Using Unified Dosimetry Index and the Impact of Conformity Index on Unified Dosimetry Index Evaluation
por: Krishnan, Jayapalan, et al.
Publicado: (2017)

Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer
por: Conibear, John, et al.
Publicado: (2018)

Monte Carlo simulations in radiotherapy dosimetry
por: Andreo, Pedro
Publicado: (2018)

Portal dosimetry in radiotherapy repeatability evaluation
por: Ślosarek, Krzysztof, et al.
Publicado: (2020)

Dosimetry audits in Taiwan radiotherapy departments
por: Shiau, An-Cheng, et al.
Publicado: (2021)

Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force
por: Stokke, Caroline, et al.
Publicado: (2017)

The role of dosimetry audit in achieving high quality radiotherapy
por: Clark, Catharine H., et al.
Publicado: (2018)

Global availability of dosimetry audits in radiotherapy: The IAEA dosimetry audit networks database
por: Izewska, Joanna, et al.
Publicado: (2018)

Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up
por: Creak, A, et al.
Publicado: (2013)

Feasibility of portal dosimetry for flattening filter‐free radiotherapy
por: Chuter, Robert W., et al.
Publicado: (2016)

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial
por: Kass-Iliyya, Antoine, et al.
Publicado: (2018)

Comparison of Dosimetric Parameters and Clinical Outcomes in Inversely Planned Intensity-Modulated Radiotherapy (IMRT) and Field-in-Field Forward Planned IMRT for the Treatment of Breast Cancer
por: Azharuddin, SK, et al.
Publicado: (2022)

Some dosimetry problems in negative pion radiotherapy
por: Baarli, Johan
Publicado: (1973)

Recent developments in absolute dosimetry for FLASH radiotherapy
por: Subiel, Anna, et al.
Publicado: (2023)

Forward and inverse effects of the complete electrode model in neonatal EEG
por: Pursiainen, S., et al.
Publicado: (2016)

Establishing a controlled hookworm human infection (CHHI) model for Africa: A report from the stakeholders meeting held in Lambaréné, Gabon, November 10–11, 2019
por: Alabi, Ayodele, et al.
Publicado: (2021)

IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer
por: Landau, David B., et al.
Publicado: (2016)

Optical fibre sensors: their role in in vivo dosimetry for prostate cancer radiotherapy
por: Woulfe, P., et al.
Publicado: (2016)

Future directions of in vivo dosimetry for external beam radiotherapy and brachytherapy
por: Verhaegen, Frank, et al.
Publicado: (2020)

Evaluation of plan robustness on the dosimetry of volumetric arc radiotherapy (VMAT) with set-up uncertainty in Nasopharyngeal carcinoma (NPC) radiotherapy
por: Ding, Zhen, et al.
Publicado: (2022)

Dosimetric impact of placement errors in optically stimulated luminescent in vivo dosimetry in radiotherapy
por: Tariq, Mahin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7jtc5susbjp41ib069vpahac99